Log in to save to my catalogue

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancr...

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancr...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7403346

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

About this item

Full title

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

Publisher

London: Nature Publishing Group UK

Journal title

British journal of cancer, 2020-08, Vol.123 (3), p.362-368

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Background
Patients with borderline resectable pancreatic cancer (BRPC) have poor prognosis with upfront surgery.
Methods
This was a single-arm Phase 2 trial for clinical and biomarker analysis. The primary endpoint is 1-year progression-free survival (PFS) rate. Patients received 8 cycles of neoadjuvant modified (m) FOLFIRINOX. Up to 6 cy...

Alternative Titles

Full title

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7403346

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7403346

Other Identifiers

ISSN

0007-0920,1532-1827

E-ISSN

1532-1827

DOI

10.1038/s41416-020-0867-x

How to access this item